Analysts think CARM stock price could increase by 1334%
Feb 09, 2025, 12:25 PM
-13.49%
What does CARM do
Carisma Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focuses on developing immunotherapies for solid tumors, including CAR-M therapies CT-0508 and CT-0525. The company went public in February 2014 and employs 107 people.
4 analysts think CARM stock price will increase by 1333.82%. The current median analyst target is $6.63 compared to a current stock price of $0.46. The lowest analysts target is $1.01 and the highest analyst target is $12.60.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
